Parathyroid hormone (1-34) (human): Precision Tool for Calcium Homeostasis and Bone Metabolism Research

Executive Summary: Parathyroid hormone (1-34) (human) is a biologically active N-terminal peptide fragment of human parathyroid hormone, consisting of 34 amino acids (MW: 4117.72 Da), and is used as a parathyroid hormone 1 receptor agonist in both in vitro and in vivo research (APExBIO). It regulates serum calcium levels by activating cAMP and inositol phosphate signaling pathways in target tissues (Huang et al., 2025). The peptide demonstrates high solubility in DMSO (≥399.3 mg/mL) and water (≥19.88 mg/mL), but is insoluble in ethanol. In preclinical models, it induces dose-dependent increases in trabecular and cortical bone mass, supporting its use in osteoporosis and bone metabolism research. It is supplied at >97.8% purity, intended for laboratory use only, and should be stored desiccated at -20°C to maintain functional stability.

Biological Rationale

Parathyroid hormone (1-34) (human) is derived from the first 34 amino acids of full-length human parathyroid hormone, secreted by the chief cells of the parathyroid glands. This peptide is the minimal fragment required for full biological activity at the parathyroid hormone 1 receptor (PTH1R), mediating critical physiological roles in calcium and phosphate homeostasis. The peptide is essential in bone remodeling, stimulating both bone formation and, at higher or continuous doses, resorption. It also modulates renal reabsorption of calcium and phosphate, and indirectly regulates intestinal calcium absorption by upregulating renal 1α-hydroxylase activity for vitamin D activation (Huang et al., 2025).

Mechanism of Action of Parathyroid hormone (1-34) (human)

PTH (1-34) acts as a parathyroid hormone 1 receptor agonist (PTH1R) and also interacts with parathyroid hormone 2 receptor (PTH2R). Upon binding to PTH1R—a G protein-coupled receptor—PTH (1-34) activates adenylate cyclase, resulting in a rapid increase in intracellular cAMP. The reported IC₅₀ for cAMP stimulation in transfected human kidney 293 cells is 0.22 nM under physiological pH and isotonic buffer conditions (APExBIO). In parallel, the peptide stimulates inositol phosphate synthesis, activating downstream protein kinase A (PKA) and protein kinase C (PKC) signaling. These cascades regulate genes involved in osteoblast differentiation, calcium transport, and 1α-hydroxylase expression. The net effect is increased bone turnover, enhanced renal reabsorption of calcium and magnesium (primarily in distal tubule and thick ascending limb), and elevated intestinal calcium uptake by promoting vitamin D activation.

Evidence & Benchmarks

• Parathyroid hormone (1-34) (human) stimulates cAMP production in human kidney 293 cells with an IC₅₀ of 0.22 nM (APExBIO, product page).
• Subcutaneous administration of 10 or 40 μg/kg/day in male Fisher 344 rats increases trabecular and cortical bone mass in a dose- and time-dependent manner (APExBIO, product page).
• In kidney assembloid models, PTH (1-34) modulates phosphate and calcium handling, providing a robust tool for modeling mineral metabolism in engineered tissues (Huang et al., 2025).
• The peptide is soluble at ≥399.3 mg/mL in DMSO and ≥19.88 mg/mL in water, but insoluble in ethanol—critical for experimental design (APExBIO, product page).
• Recent reviews highlight PTH (1-34)'s reproducible activity and utility as a benchmark agonist in bone and kidney research (Amyloid.co).

Applications, Limits & Misconceptions

Parathyroid hormone (1-34) (human) is validated for use in cellular assays, organoid modeling, and animal studies investigating bone formation, mineral metabolism, and kidney physiology. It is a central tool for interrogating PTH/PTHrP receptor signaling, dissecting calcium homeostasis, and benchmarking osteoporosis models. High-purity lots from APExBIO ensure reproducibility in quantitative signal transduction studies (product page).

This article extends prior coverage by integrating recent advances in spatially patterned kidney assembloid research (BVT948.com), emphasizing the peptide's role in high-fidelity modeling of renal and bone processes. For a protocol-focused perspective, see PeptideBridge, which details troubleshooting and workflow design. For further discussion on bone-kidney interplay, this article addresses translational research frontiers.

Common Pitfalls or Misconceptions

• PTH (1-34) is not suitable for diagnostic or therapeutic use in humans; it is for research only (APExBIO, product documentation).
• The peptide is unstable in solution at room temperature or in aqueous buffers for extended periods; always prepare fresh aliquots to avoid loss of activity (APExBIO).
• It does not fully recapitulate all actions of full-length PTH, particularly at PTH2R, where the C-terminal region may affect receptor selectivity (Huang et al., 2025).
• Misuse in ethanol-based solvents will result in precipitation and loss of function (APExBIO).
• Continuous high-dose exposure in vivo may lead to bone resorption rather than formation; dosing regimens must be carefully controlled (APExBIO).

Workflow Integration & Parameters

For experimental use, PTH (1-34) (human) should be reconstituted in DMSO (≥399.3 mg/mL) or water (≥19.88 mg/mL) under sterile, desiccated conditions. Store lyophilized powder at -20°C, protected from moisture and light. For in vitro studies, dilute freshly to working concentrations in physiological buffer, minimizing freeze-thaw cycles. For in vivo animal studies, subcutaneous dosing at 10–40 μg/kg/day is standard for bone mass modulation in rodent models. Avoid ethanol as a solvent due to insolubility. Use validated controls and ensure peptide integrity by analytical HPLC or mass spectrometry prior to use for critical assays. Refer to the A1129 kit for batch-specific purity and solubility specifications. For advanced spatially patterned kidney assembloid applications, titrate dosing based on organoid size and assay endpoints (Huang et al., 2025).

Conclusion & Outlook

Parathyroid hormone (1-34) (human) remains a gold-standard parathyroid hormone 1 receptor agonist and calcium homeostasis regulator for bone and kidney research. Its high solubility, purity, and well-characterized mechanism support precision studies in cell signaling, assembloid modeling, and translational osteoporosis models. The ongoing development of complex kidney assembloid systems, as demonstrated in recent literature, further expands its utility in regenerative medicine and disease modeling (Huang et al., 2025). For comprehensive protocols, troubleshooting, and updated reference standards, consult the product page and linked resources.